American Oriental Bioengineering Stock Gaps Down On Today's Open (AOB)

NEW YORK ( TheStreet) -- Shares of American Oriental Bioengineering (NYSE: AOB) were gapping down Tuesday morning with an open price 14.7% lower than Monday's closing price. The stock closed at $2.25 Monday and opened today's trading at $1.92.

The average volume for American Oriental Bioengineering has been 404,300 shares per day over the past 30 days. American Oriental Bioengineering has a market cap of $18 million and is part of the health care sector and drugs industry. Shares are down 6.3% year to date as of the close of trading on Monday.

American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of a range of pharmaceutical and healthcare products. The company has a P/E ratio of 7.2, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 16.1.

TheStreet Ratings rates American Oriental Bioengineering as hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. You can view the full American Oriental Bioengineering Ratings Report.

Get more investment ideas from our investment research center.

Interested in other stocks that are gapping down? Get free SMS text alerts sent to you when the action happens by texting DOWN to 95370 or select from multiple alert options.

null

More from Markets

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)